Synthesis of the Fmoc-Lys(Myristoyl)-OH building block for peptide synthesis
Reagents and conditions: a) N-Hydroxysuccinimide, DCC, room temperature, 2 hrs. b) Fmoc-Lys-OH, i Pr 2 NEt, room temperature, overnight.
To a solution of myristic acid 1 (2.28 g, 10 mmol) in anhydrous N, N'-dimethylformamide (DMF, 20 mL) , N-hydroxysuccinimide (1.15 g, 10 mmol) was added with stirring at room temperature. Then N,N'-dicyclohexylcarbodiimide (DCC, 2.06 g, 10 mmol) in anhydrous DMF (20 mL) was added to the reaction. After stirring at room temperature for 2 hrs, the reaction mixture was filtered. The filtrate was added to a solution of Fmoc-Lys-OH (3.68 g, 10 mmol) with N,N-diisopropylethylamine (DIEA, 1.74 mL, 10 mmol) in anhydrous DMF (20.0 mL) at room temperature. The resulting reaction mixture was stirred for another 24 hrs at room temperature. Then the reaction mixture was poured into water and neutralized with 1 M HCl to adjust pH to 2~3. The precipitate was collected by filtration and dried to give the crude. Then the crude compound was purified by silica gel column chromatography using 50:1 CH2Cl2:CH3OH to give compound 2a as a white solid (5.03 g, 87% yield 141.2, 127.3, 126.7, 124.9, 124.8, 119.5, 66.6, 53.8, 38.6, 35.8, 31.6, 30.9, 29.4, 29.3, 29.3, 29.2, 29.0, 28.9, 28.5, 25.7,22.9, 22.3, 13.0 Synthesis of peptide Ac-Glu-Ala-Leu-Pro-Lys-Lys(Acyl)-(7-amino-4-methyl-coumarin) Ac-Glu-Ala-Leu-Pro-Lys-Lys(Myristoyl)-(7-amino-4-methyl-coumarin) (4a). A protected peptide AcGlu( t Bu)Ala-Leu-Pro-Lys(Boc)Lys(Myr)OH was synthesized by solid phase peptide synthesis using a 2-chlorotrityl resin and then cleaved from support under mild conditions (AcOH: CF 3 CH 2 OH: CH 2 Cl 2 , 1:1:8, v/v/v). To a solution of AcGlu( t Bu)Ala-Leu-Pro-Lys(Boc)Lys(Myr)OH (50 mg, 0.046 mmol) and N-methylmorpholine (NMM, 0.01 mL, 0.091 mmol) in dry dichloromethane (2 mL), isobutylchloroformate (0.009 mL, 0.067 mmol) was added dropwisely at 0°C. The reaction mixture was stirred for 2 hrs at 0°C. 7-amino-4-methyl-coumarin (16mg, 0.091mmol) in DMF (2 mL) was added at 0°C and the reaction mixture was stirred 24 hrs at room temperature. Then the solution was partitioned between CH 2 Cl 2 (10ml) and brine (10ml). The aqueous phase was extracted with CH 2 Cl 2 (2×15ml). The combined organic phase was dried over anhydrous MgSO 4 and then evaporated to dryness. The obtained residue was treated with 1% triisopropylsilane in TFA (1mL). After stirring for 2 hrs, the reaction mixture was evaporated to dryness, and then co-evaporated with toluene and MeCN. The resulting residue was applied to preparative HPLC purification. Peptide 4a was eluted at 62 mins with a flow rate of 10 ml/min. The gradient was: 0% solvent B for 10 min, 0% to 80% solvent B over 50 mins, then 80% to 95% solvent B for 5 mins. After lyophilization the desired peptide 4a was obtained as a white solid (4a, 12 mg, 23.8% Ac-Glu-Ala-Leu-Pro-Lys-Lys(Ac)-(7-amino-4-methyl-coumarin) (4b) Peptide 4b was synthesized with the same synthetic method of peptide 4a and peptide 4b was eluted at 61 mins with a flow rate of 10 ml/min. The gradient was: 0% solvent B for 10 mins, 0% to 40% solvent B over 50 mins, then 40% to 95% solvent B for 5 mins. After lyophilization the desired peptide 4b was obtained as a white solid (4b, 20.5%). LCMS (ESI) calcd. for C 45 H 67 N 9 O 12 [M+H] + 926.5, obsd. 926.7.
Ac-Glu-Ala-Leu-Pro-Lys-Lys-(7-amino-4-methyl-coumarin) (4c) Peptide 4c was synthesized with the same synthetic method of peptide 4a and peptide 4c was eluted at 57 min with a flow rate of 10 ml/min. The gradient was: 0% solvent B for 10 mins, then 0% to 30% solvent B over 50 mins. After lyophilization the desired peptide was obtained as a white solid (4c, 21.0% Monitoring trypsin-catalyzed hydrolysis of AMC-free lysine peptides. Trypsin (5 mg/mL, 60 L) was added to a 60 L solution containing the AcEALPKK-AMC peptide (10 M), NAD (1 mM) and dithiothreitol (DTT, 1 mM) in Tris-HCl buffer (pH 8.0, 20 mM). The reaction mixture was incubated for 0.5, 1, 2, 3, 4, 6 or 8 hrs at 37°C. The mixture (100 L) was transferred to a 96 well plate and the fluorescence was recorded by a plate reader.
Testing the Sirt6 fluorogenic assay with different concentration of the AMC-myristoyl lysine peptide. Sirt6 (1 M) was incubated with AcEALPK(MyrK)-AMC peptide (1~20 M), NAD (1 mM), BSA(1 mg/mL), and dithiothreitol (DTT, 1 mM) in Tris-HCl buffer (pH 8.0, 20 mM) in a 60 L reaction for 2 hrs at 37°C. Then trypsin (5 mg/mL, 60 L) containing nicotinamide (8 mM) was added and the reactions were incubated for 2 hrs at 37°C. Then the mixture (100 L) was transferred to a 96-well plate and the fluorescence was recorded by a plate reader.
Testing the Sirt6 fluorogenic assay with different enzyme concentration. Sirt6 (0.1~2M) was incubated with AcEALPK(MyrK)-AMC peptide (10 M), NAD (1 mM), BSA(1 mg/mL), and dithiothreitol (DTT, 1 mM) in Tris-HCl buffer (pH 8.0, 20 mM) in a 60 L reaction for 2 hrs at 37°C. Then trypsin (5 mg/mL, 60 L) containing nicotinamide (8 mM) was added and the reactions were incubated for 2 hrs at 37°C. Then the mixture (100 L) was transferred to a 96-well plate and the fluorescence was recorded by a plate reader.
Sirt6 fluorogenic assay with Ac-Glu-Ala-Leu-Pro-Lys-Lys(Acyl)-(7-amino-4-methylcoumarin). Sirt6 (1 M) was incubated with AcEALPK(AcylK)-AMC peptide (10 M), NAD (1 mM), BSA(1 mg/mL), and dithiothreitol (DTT, 1 mM) in Tris-HCl buffer (pH 8.0, 20 mM) in a 60 L reaction for 2 hrs at 37°C. Then trypsin (5 mg/mL, 60 L) containing nicotinamide (8 mM) was added and the reactions were incubated for 2 hrs at 37°C. Then the mixture (100 L) was transferred to a 96-well plate and the fluorescence was recorded by a plate reader.
Testing Sirtuin inhibitors with Ac-Glu-Ala-Leu-Pro-Lys-Lys(Myristoyl)-(7-amino -4-methyl-coumarin) for their ability to inhibit Sirt6. Sirt6 (1 M) was first incubated with sirtuin inhibitors (200 M from DMSO stock solution), NAD (1 mM), BSA(1 mg/mL) in Tris-HCl buffer (pH 8.0, 20 mM) containing dithiothreitol (DTT, 1 mM) for 0.5 hour at 37°C. Then the substrate AcEALPK(MyrK)-AMC (10 M) was added to initiate the demyristoylation reaction. The total reaction volume was 60 L. The reactions were incubated for 2 hrs at 37°C. Then trypsin (5 mg/mL, 60 L) containing nicotinamide (8 mM) was added and the reactions were incubated for 2 hrs at 37°C. The mixture (100 L) was transferred to a 96-well plate and the fluorescence was recorded by a plate reader.
Dose-response of nicotinamide with Sirt6 using the fluorogenic assay. Sirt6 (1 M) was first incubated with nicotinamide (2 M to 2mM from water stock solution), NAD (1mM), BSA(1mg/mL) in Tris-HCl buffer (pH 8.0, 20 mM) containing dithiothreitol (DTT, 1 mM) for 0.5 hours at 37°C. Then the substrate AcEALPK(MyrK)-AMC (10 M) was added to initiate the demyristoylation reaction and the reaction (60 L) was incubated for 2 hrs at 37°C . Then trypsin (5 mg/mL, 60 L) containing nicotinamide (8 mM) was added and the resulting reaction mixtures were incubated for 2 hrs at 37°C. The reaction mixtures (100 L) were transferred to a 96-well plate and the fluorescence was recorded by using a plate reader.
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peptide on Sirt6. The AcEALPK(MyrK)-AMC peptide concentration was varied from 1 to 128 μM. The reactions (60 L with 1 mM NAD, 20 mM Tris, pH 8.0, 1 mM DTT, 1 mg/mL BSA, 0.2 μM Sirt6 and the peptide at different concentrations) were incubated for 60 mins at 37°C. Each reaction was stopped using 60 L of 0.5N HCl in methanol. The reaction mixtures were spun at 18000g for 10 min and we analyzed on a Kinetex XB-C18 column (100A, 100 mm × 4.60 mm, 2.6 μm, Phenomenex). The gradient of 0 to 40% B in 17 mins and then 40% to 100% for 2 mins at 0.5 mL/min was used. The product and the substrate peaks were quantified using absorbance at 326 nM and converted to initial rates, which were then plotted against the peptide concentrations and fitted using Kaleidagraph. Figure S9 . LCMS of Ac-Glu-Ala-Leu-Pro-Lys-Lys-(7-amino-4-methyl-coumarin) 
